Alnylam's siRNAs reach the liver; Depovax cancer vaccine shows efficacy in Phase I;

> Alnylam Pharmaceuticals ($ALNY) has presented data that show that Alnylam's GalNAc-conjugate siRNAs are taken up into the liver and silence the target genes. These are part of Alnylam's "Alnylam 5x15" product development strategy, and IND submissions are expected in 2012 and 2013. Press release

> Acino has inaugurated a new pharmaceutical manufacturing plant for transdermal therapeutic systems in Miesbach, Germany. Article

> Immunovaccine's DPX-0907 cancer vaccine, which uses the company's DepoVax adjuvanting delivery platform, shows an immune response in Phase I. Press release

> AcelRx Pharmaceuticals has gained two additional U.S. patents for small-volume oral transmucosal dosage forms. Press release

> CareFusion has been hit with a recall of an infusion pump component; this is the company's third Class I recall in two months. Article

> Nanoparticle-corked carbon nanotubes could carry drug payloads. Article

> Chitosan-based mucoadhesive tablets have potential for the oral delivery of ibuprofen. Abstract

And Finally… A 13-year-old student developing a cancer drug delivery technology using carbon nanotubes and targeting cancer stem cells is one of 10 finalists in the Discovery 3M Young Scientist Challenge. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.